These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38759761)

  • 1. Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD.
    Chapman MB; Norwood DA; Price C; Abdulhadi B; Kyanam Kabir Baig K; Ahmed AM; Peter S; Routman JS; Sánchez-Luna SA; Duggan EW; Mulki R
    Gastrointest Endosc; 2024 Nov; 100(5):923-927. PubMed ID: 38759761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients.
    Nadeem D; Taye M; Still MD; McShea S; Satterfield D; Dove JT; Wood GC; Addissie BD; Diehl DL; Johal AS; Khara HS; Confer BD; Still CD
    Gastrointest Endosc; 2024 Oct; 100(4):745-749. PubMed ID: 38692518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
    Samuels JM; Niswender KD; Roumie CL; Spann MD; Flynn CR; Ye F; Blankush J; Irlmeier R; Funk LM; Patel MB
    Diabetes Obes Metab; 2024 Sep; 26(9):3906-3913. PubMed ID: 38934217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, adherence and persistence of various glucagon-like peptide-1 agonists: nationwide real-life data.
    Kassem S; Khalaila B; Stein N; Saliba W; Zaina A
    Diabetes Obes Metab; 2024 Oct; 26(10):4646-4652. PubMed ID: 39109455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.
    Garza K; Aminpour E; Shah J; Mehta B; Early D; Gyawali CP; Kushnir V
    Am J Gastroenterol; 2024 Jun; 119(6):1081-1088. PubMed ID: 38534127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
    Xue X; Ren Z; Zhang A; Yang Q; Zhang W; Liu F
    Int J Clin Pract; 2016 Aug; 70(8):649-56. PubMed ID: 27456750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
    Wu F; Smith MR; Mueller AL; Klapman SA; Everett LL; Houle T; Kuo B; Hobai IA
    Can J Anaesth; 2024 Jul; 71(7):958-966. PubMed ID: 38485835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions.
    Jalleh RJ; Rayner CK; Hausken T; Jones KL; Camilleri M; Horowitz M
    Lancet Gastroenterol Hepatol; 2024 Oct; 9(10):957-964. PubMed ID: 39096914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
    Samson SL; Garber AJ
    Curr Diab Rep; 2016 Dec; 16(12):120. PubMed ID: 27766579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) on Food Content During Esophagogastroduodenoscopy (EGD).
    Stark JE; Cole JL; Ghazarian RN; Klass MJ
    Ann Pharmacother; 2022 Aug; 56(8):922-926. PubMed ID: 34726082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Fang L; Li J; Zeng H; Liu J
    Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
    Almeida OP; Fong Z; Hill Almeida LM; Sanfilippo FM; Page A; Etherton-Beer C
    Diabetes Obes Metab; 2024 Jul; 26(7):2925-2932. PubMed ID: 38650544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.